NCT07005154View on ClinicalTrials.gov

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

218

Participants

Timeline

Start Date

June 19, 2025

Primary Completion Date

May 31, 2032

Study Completion Date

May 31, 2032

Conditions
Prostate CancerMetastatic Castration-Resistant Prostate CancerMetastatic Hormone Sensitive Prostate Cancer
Interventions
DRUG

ASP5541

Intramuscular Injection

DRUG

Prednisone

Oral

DRUG

Prednisolone

Oral

DRUG

abiraterone acetate

Oral

Trial Locations (4)

29572

RECRUITING

Carolina Urologic Research Center, Myrtle Beach

87109

RECRUITING

New Mexico Oncology Hematology Consultants, Albuquerque

Unknown

RECRUITING

Shizuoka Cancer Center, Sunto-gun

RECRUITING

The Cancer Institute Hospital of JFCR, Koto-ku

All Listed Sponsors
lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT07005154 - A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer | Biotech Hunter | Biotech Hunter